Novel PNPT1-ALK fusion variant exerted significant benefit to crizotinib in NSCLC
Section snippets
Declaration of Competing Interest
None.
Acknowledgements
We thank Mingzhe Xiao, Chuang Qi, Yuan Wu, Lijian Li and Chao Song from Jiangsu Simcere Diagnostics for the kindly assistance. This work was supported by National Natural Science Foundation of China under Grant No. 81800090.
References (5)
- et al.
ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung Cancer
J. Thorac. Oncol.
(2009) - et al.
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
Ann. Oncol.
(2018)
There are more references available in the full text version of this article.
Cited by (2)
Functional consequence and therapeutic targeting of cryptic ALK fusions in monosomy 7 acute myeloid leukemia
2023, Pediatric Blood and CancerSP1 and NFY Regulate the Expression of PNPT1, a Gene Encoding a Mitochondrial Protein Involved in Cancer †
2022, International Journal of Molecular Sciences
- 1
Linling Jin and Yanli Wang contributed equally to the manuscript.
© 2020 Elsevier B.V. All rights reserved.